Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with FGFR mRNA-positive advanced/metastatic UC previously treated with platinum chemotherapy.
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression / Sternberg, C.N., Petrylak, D.P., Bellmunt, J., Nishiyama, H., Necchi, A., Gurney, H., Lee, J., Van Der Heijden, M.S., Rosenbaum, E., Penel, N., Pang, S., Li, J., García Del Muro, X., Joly, F., Pápai, Z., Bao, W., Ellinghaus, P., Lu, C., Sierecki, M., Coppieters, S., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 41:3(2023), pp. 629-639. [10.1200/JCO.21.02303]
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
Necchi, Andrea;
2023-01-01
Abstract
Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with FGFR mRNA-positive advanced/metastatic UC previously treated with platinum chemotherapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
sternberg-et-al-2022.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
305.85 kB
Formato
Adobe PDF
|
305.85 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
